Khaitan & Co Advises Molbio Diagnostics on ₹939 Crore India IPO

• Molbio Diagnostics Limited raised ₹939.696 crore from its initial public offering (IPO) of equity shares.
• The IPO was advised by Khaitan & Co, with a team led by Abhimanyu Bhattacharya and Gautham Srinivas.
• Cyril Amarchand Mangaldas advised the lead managers on the IPO, while Hogan Lovells and Cadwalader, Wickersham & Taft acted as international counsel.
• Molbio Diagnostics is an innovative point-of-care diagnostics company focused on expanding access to accurate healthcare technologies.

The success of its IPO demonstrates the increasing demand for innovative healthcare solutions in the country.

Molbio Diagnostics Limited has successfully completed its initial public offering (IPO) of equity shares, raising ₹939.696 crore from investors. The IPO consisted of a fresh issue and an offer for sale. This significant transaction marks a major milestone for the company, which is focused on expanding access to accurate, rapid, and cost-effective healthcare technologies.

The IPO was advised by Khaitan & Co, with a team led by Abhimanyu Bhattacharya (Partner), Gautham Srinivas (Partner), and Sathvik Ponnappa (Partner). The team included several other lawyers from the firm, including Sanjeev Chowdhary, Vaishnavi Gupta, Mainak Pani, and Shambhavi Gautam.

The IPO process in India is subject to various regulations and guidelines set by the Securities and Exchange Board of India (SEBI). The lead managers for the IPO, including Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, and Motilal Oswal Investment Advisors Limited, were advised by Cyril Amarchand Mangaldas. The transaction was led by Yash J. Ashar (Senior Partner) and Priyadarshini Rao (Partner), with assistance from Raksha Raina and several associates.

The international counsel for the lead managers was provided by Hogan Lovells and Cadwalader, Wickersham & Taft, with Biswajit Chatterjee (then of Hogan Lovells) leading the team.

This transaction highlights the growing importance of point-of-care diagnostics companies in India. Molbio Diagnostics is a pioneering company focused on expanding access to accurate and cost-effective healthcare technologies. The success of its IPO demonstrates the increasing demand for innovative healthcare solutions in the country.

Lawyers advising clients on Indian IPOs should note that transactions like this one may require specialized expertise and compliance considerations, particularly when dealing with companies operating in the diagnostics sector.

Lawyers advising clients on Indian IPOs should note that this transaction highlights the growing importance of point-of-care diagnostics companies, which may require specialized expertise and compliance considerations.

Source: Original reporting via Bloomberg Law